A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

NCT06348199 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

555

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer Stage IV

Interventions

DRUG: SB27
DRUG: Keytruda

Sponsor

Samsung Bioepis Co., Ltd.